A phase II, non-randomized study of abraxane plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer: Evaluation of side effects and tolerability

16556 Background: Paclitaxel and carboplatin are currently used as a standard therapy for recurrent platinum-sensitive ovarian cancer. However Paclitaxel is solubilized in cremophor which is responsible for some paclitaxel associated hypersensitivity. Abraxane is a Cremophor EL-free, albumin-bound nanoparticle paclitaxel developed to reduce the toxicities associated with Cremophor. This study was designed to evaluate the efficacy and safety of Abraxane for the treatment of recurrent ovarian cancer. Methods: Patients with recurrent platinum-sensitive ovarian or primary peritoneal carcinoma with Measurable Disease to receive Abraxane: 100 mg/m2: day 1, 8, 15, and Carboplatin AUC 5 day 1 every 28 days intravenously for 6 cycles. Response rate and safety will be assessed. 22 patients enrolled. Results: 19 patients completed 6 cycles of chemotherapy with partial or complete response. No hypersensitivity reaction was reported. 4 cases of more than Grade 3 neutropenia were found and 2 cases of more than grade 3 ...